Hologic price target lowered to $71 from $90 at Raymond James

Raymond James lowered the firm’s price target on Hologic (HOLX) to $71 from $90 and keeps an Outperform rating on the shares. Hologic’s Q2 was in line on revenues with a slightly better EPS, but the company cut guidance due almost exclusively to tariff headwinds, primarily the 10% rate applied to Costa Rica, as well as the China trade war, the analyst tells investors in a research note. Raymond James thinks the business’s ability to grow while leading in the markets it plays in is underappreciated.